RMD Open (Sep 2020)

Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic

  • Alain Cantagrel,
  • Anne-Priscille Trouvin,
  • Serge Perrot,
  • Daniel Wendling,
  • Florian Bailly,
  • Philippe Bertin,
  • Thierry Thomas,
  • Thibaud Lansaman,
  • Laurent Grange,
  • Calogera Dovico

DOI
https://doi.org/10.1136/rmdopen-2020-001326
Journal volume & issue
Vol. 6, no. 2

Abstract

Read online

Pain in rheumatic diseases is primarily due to mechanical or inflammatory mechanism, but neuropathic pain (NP) component is also occurring in many conditions and is probably underdiagnosed. The purpose of this article is to provide an overview of prevalence, pathophysiological and currently available treatment of NP in rheumatic diseases. When associated with clinical evaluation assessing neurological clinical signs and neuroanatomical distribution, Douleur Neuropathique 4 Questions, painDETECT, Leeds assessment of neuropathic symptoms and signs and Neuropathic Pain Questionnaire can detect NP component. Inflammatory or connective diseases, osteoarthritis, back pain or persistent pain after surgery are aetiologies that all may have a neuropathic component. Unlike nociceptive pain, NP does not respond to usual analgesics such as paracetamol and non-steroidal anti-inflammatory drugs. Entrapment neuropathy, peripheral neuropathy or small-fibre neuropathy are different aetiologies that can lead to NP. A part of the pain labelled neuropathic is rather nociplastic, secondary to a central sensitisation mechanism. Identifying the right component of pain (nociceptive vs neuropathic or nociplastic) could help to better manage pain in rheumatic diseases with pharmacological and non-pharmacological treatments.